[1]
|
Craig, N.J., Alonso, M.B.D., Hawker, K.L., Shiels, P., Glencorse, T.A., Campbell, J.M., Bennett, N.K., Canham, M., Donald, D., Gardiner, M., Gilmore, D.P., MacDonald, R.J., Maitland, K., McCallion, A.S., Russell, D., Payne, A.P., Sutcliffe, R.G. and Davies, R.W. (2001) A candidate gene for human neurodegenerative disorders: A rat PKC gamma mutation causes a Parkinsonian syndrome. Nature Neuroscience, 4, 1061-1062.
doi:10.1038/nn740
|
[2]
|
Clarke, D.J. and Payne, A.P. (1994) Neuroanatomical characterization of a new mutant rat with dopamine depletion in the substantia nigra. European Journal of Neuroscience, 6, 885-888. doi:10.1038/nn740
|
[3]
|
Payne, A.P., Sutcliffe, R.G., Campbell, J.M., Favor, G., Russell, D., Bennett, N.K., Clarke, D.J., Branton, R., Davies, R.W., Simpson, E., Tsang, C. and Baxendale, R.H. (1998) Disordered locomotion in the AS/AGU mutant rat and the effects of L-DOPA or fetal midbrain grafts. Movement Disorders, 13, 832-834.
doi:10.1002/mds.870130514
|
[4]
|
Campbell, J.M., Gilmore, D.P., Russell, D., Growney, C.A., Favor, G., Weir, J., Stone, T.W. and Payne, A.P. (1998) Extracellular levels of dopamine and its metabolite 3,4-dihydroxy-phenylacetic acid measured by microdialysis in the corpus striatum of conscious AS/AGU mutant rats. Neuroscience, 85, 323-325.
doi:10.1016/S0306-4522(98)00053-0
|
[5]
|
Al-Fayez, M., Russell, D., Davies, R.W., Shiels, P., Baker, P.J. and Payne, A.P. (2005) Deficits in the midbrain raphe nuclei and striatum of the AS/AGU rat: A protein kinase C-g mutant. European Journal of Neuroscience, 22, 2792-2798. doi:10.1111/j.1460-9568.2005.04502.x
|
[6]
|
Lam, A.G., Campbell, J.M., Bennett, N.K., Payne, A.P., Davies, R.W., Sutcliffe, R.G. and McCulloch, J. (1998) Local cerebral glucose utilization in the AS/AGU rat: A mutant with movement disorders. European Journal of Neuroscience, 10, 1963-1967.
doi:10.1046/j.1460-9568.1998.00206.x
|
[7]
|
Payne, A.P., Campbell, J.M., Russell, D., Favor, G., Sutcliffe, R.G., Bennett, N.K., Davies, R.W. and Stone, T.W. (2000) The AS/AGU rat: A spontaneous model of disruption and degeneration in the nigrostriatal dopaminergic system. Journal of Anatomy, 196, 629-633.
doi:10.1046/j.1469-7580.2000.19640629.x
|
[8]
|
Choi, W.S., Yoon, S.Y., Oh, T.H., Choi, E.J., O’Malley, K.L. and Oh, Y.J. (1999) Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: Role of caspases, ROS, and JNK. Journal of Neuroscience Research, 57, 86-94.
doi:10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E
|
[9]
|
Tatton, N.A. and Kish, S.J. (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyltransferase labelling and acridine orange staining. Neuroscience, 77, 1037-1048.
doi:10.1016/S0306-4522(96)00545-3
|
[10]
|
Spooren, W.P., Gentsch, C. and Wiessner, C. (1998) TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 85, 649-651.
|
[11]
|
Serra, P.A., Sciola, L., Delogu, M.R., Spano, A., Monaco, G., Miele, E., Rocchitta, G., Miele, M., Migheli, R. and Desole, M.S. (2002) The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia: Relevance to nigral neuronal death and striatal neurochemical changes. Journal of Biological Chemistry, 277, 34451-34461.
doi:10.1074/jbc.M202099200
|
[12]
|
Oztas, E. and Topal, T. (2003) A cell protective mechanism in a murine model of Parkinson’s disease. Turkish Journal of Medical Sciences, 33, 295-299.
|
[13]
|
Schwarting, R.K.W. and Huston, J.P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Progress in Neurobiology, 50, 275-331.
doi:10.1016/S0301-0082(96)00040-8
|
[14]
|
Flint, B.M. (2001) Experimental models of Parkinson’s disease. Nature Reviews Neuroscience, 2, 325-332.
|
[15]
|
Forno, L.S., DeLanney, L.E., Irwin, I. and Langston, J.W. (1993) Similarities and differences between MPTP-induced parkinsonsim and Parkinson’s disease. Neuropathologic considerations. Advanced Neurology, 60, 600-608.
|
[16]
|
Dauer, W. and Przedborski, S. (2003) Parkinson’s disease: Mechanisms and models. Neuron, 39, 889-909.
doi:10.1016/S0896-6273(03)00568-3
|
[17]
|
Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V. and Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience, 3, 1301-1306.
doi:10.1038/81834
|
[18]
|
Paxinos, G. and Watson, C. (1982) The rat brain in stereotaxic coordinates. Academic Press, Waltham.
|
[19]
|
Shi, S.R., Key, M.E. and Kalra, K.L. (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. Journal of Histochemistry & Cytochemistry, 39, 741-748.
doi:10.1177/39.6.1709656
|
[20]
|
Norton, A.J., Jordan, S. and Yeomans, P. (1994) Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues. The Journal of Pathology, 173, 371-379. doi:10.1002/path.1711730413
|
[21]
|
Muqit, M.M.K., Davidson, S.M., Smith, M.D.P., MacCormac, L.P., Kahns, S., Jensen, P.H., Wood, N.W. and Latchman, D.S. (2004) Parkin is recruited into aggresomes in a stress-specific manner: Over-expression of parkin reduces aggresome formation but can be dissociated from parkin’s effect on neuronal survival. Human Molecular Genetics, 13, 117-135.
doi:10.1093/hmg/ddh012
|
[22]
|
Campbell, J. M., Payne, A.P., Gilmore, D.P., Byrne, J.E., Russell, D., McGadey, J., Clarke, D.J., Branton, R., Davies, R.W. and Sutcliffe, R.G. (1997) Age changes in dopamine levels in the corpus striatum of Albino Swiss (AS) and AS/AGU mutant rats. Neuroscience Letters, 239, 54-56. doi:10.1016/S0304-3940(97)00871-9
|
[23]
|
Campbell, J.M., Payne, A.P., Gilmore, D.P., Byrne, J.E., Russell, D., McGadey, J., Clarke, D.J., Davies, R.W. and Sutcliffe, R.G. (1996) Neostriatal dopamine depletion and locomotor abnormalities due to the Albino Swiss rat agu mutation. Neuroscience Letters, 213, 173-176.
|
[24]
|
Roffler-Tarlov, S. and Graybiel, A.M. (1984) Weaver mutation has differential effects on the dopamine-containing innervation of the limbic and non-limbic striatum. Nature, 307, 62-66. doi:10.1038/307062a0
|
[25]
|
Hornykiewicz, O. (1995) Striatal dopamine in dopa-responsive dystonia: Comparison with idiopathic Parkinson’s disease and other dopamine-dependent disorders. In: Segawa, M. and Nomura, Y., Ed., Age-Related Dopamine-Dependent Disorders, Karger, Basel, 101-108
|
[26]
|
Leenders, K.L., Palmer, A.J., Quinn, N., Clark, J.C., Firnau, G., Garnett, E.S., Nahmias, C., Jones, T. and Marsden, C.D. (1986) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. Journal of Neurology, Neurosurgery & Psychiatry, 49, 853-860. doi:10.1136/jnnp.49.8.853
|
[27]
|
Leenders, K.L., Salmon, E.P., Tyrrell, P., Perani, D., Brooks, D.J., Sager, H., Jones, T., Marsden, C.D. and Frackowiak, R.S. (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Archives of Neurology, 47, 1290-1298.
doi:10.1001/archneur.1990.00530120034007
|
[28]
|
Moratalla, R., Quinn, B., DeLanney, L.E., Irwin, I., Langston, J.W. and Graybiel, A.M. (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences of USA, 89, 3859-3863.
doi:10.1073/pnas.89.9.3859
|
[29]
|
Snow, B.J., Vingerhoets, F.J., Langston, J.W., Tetrud, J.W., Sossi, V. and Calne, D.B. (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. Journal of Neurology, Neurosurgery & Psychiatry, 68, 313-316.
|
[30]
|
Lennox G., Lowe J., Morrell K., Landon M., and Mayer R.J. (1989) Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. Journal of Neurology, Neurosurgery & Psychiatry, 52, 67-71.
doi:10.1136/jnnp.68.3.313
|
[31]
|
Love, S. and Nicoll, J.A. (1992) Comparison of modified Bielschowsky silver impregnation and anti-ubiquitin immunostaining of cortical and nigral Lewy bodies. Neuropathology and Applied Neurobiology, 18, 585-592.
doi:10.1111/j.1365-2990.1992.tb00830.x
|
[32]
|
Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L. and Goedert, M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neuroscience Letters, 251, 205-208.
doi:10.1016/S0304-3940(98)00504-7
|
[33]
|
Irizarry, M.C., Growdon, W., Gomez-Isla, T., Newell, K., George, J.M., Clayton, D.F. and Hyman, B.T. (1998) Nigral and cortical Lewy bodies and dystrophic nigralneurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. Journal of Neuropathology & Experimental Neurology, 57, 334-337. doi:10.1097/00005072-199804000-00005
|
[34]
|
Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T. and Tanaka, K. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics, 25, 302-305. doi:10.1038/77060
|
[35]
|
Sherman, M.Y. and Goldberg, A.L. (2001) Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron, 29, 15-32.
doi:10.1016/S0896-6273(01)00177-5
|
[36]
|
Cookson, M.R. (2005) The biochemistry of Parkinson’s disease. Annual Review of Biochemistry, 74, 29-52.
doi:10.1146/annurev.biochem.74.082803.133400
|
[37]
|
Gai, W.P., Yuan, H.X., Li, X.Q., Power, J.T., Blumbergs, P.C. and Jensen, P.H. (2000) In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Experimental Neurology, 166, 324-333. doi:10.1006/exnr.2000.7527
|
[38]
|
McNaught, K.S., Shashidharan, P., Perl, D.P., Jenner, P., and Olanow, C.W. (2002) Aggresome-related biogenesis of Lewy bodies. European Journal of Neuroscience, 16, 2136-2148. doi:10.1046/j.1460-9568.2002.02301.x
|
[39]
|
Moreno-Gonzalez, I and Soto, C. (2011) Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission. Seminars in Cell & Developmental Biology, 22, 482-487. doi:10.1016/j.semcdb.2011.04.002
|
[40]
|
McNaught, K.S., Perl, D.P., Brownell, A.L. and Olanow, C.W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Annals of Neurology, 56, 149-162. doi:10.1002/ana.20186
|
[41]
|
Huang, Q. and Figueiredo-Pereira, M.E. (2010) Ubiquitin/ proteasome pathway impairment in neurodegeneration: Therapeutic implications. Apoptosis, 15, 1292-1311.
doi:10.1007/s10495-010-0466-z
|
[42]
|
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608. doi:10.1007/s10495-010-0466-z
|
[43]
|
Kumar, K.R., Djarmati-Westenberger, A. and Grünewald, A. (2011) Genetics of Parkinson’s disease. Seminars in Neurology, 31, 433-40. doi:10.1055/s-0031-1299782
|